Provider profile · Compounded treatment
PriorityMeds / RXPros review: services, costs, and questions
PriorityMeds' announced transition to RXPros, compounded offerings, and account and billing questions for existing patients.
What the official information says
PriorityMeds' official website states that it is now part of RXPros. It says RXPros manages accounts, renewals, support, and transferred billing history. These are company statements about the transition, not independently audited continuity guarantees.
The page advertises compounded tirzepatide with B6 and compounded semaglutide with B12. Its dosing menu and trial-style weight-loss figures should not be taken as a clinician's individualized instructions or as evidence for those compounded combinations.
Pricing and the full bill
The retrieved page displays semaglutide at $99.99 and tirzepatide at $144.97 per month, described as including the doctor visit and shipping. Confirm actual payment intervals, existing-patient pricing, pharmacy charges, and cancellation terms under RXPros; do not assume the old PriorityMeds agreement remains unchanged.
A first-month price is not a reliable annual budget. Ask for the amount charged today, the renewal interval, the cost after any promotion, and whether medication, supplies, visits, labs, and shipping are included. Obtain cancellation and refund terms before paying, particularly if a prescription has not yet been approved.
Limitations that affect your decision
Existing patients should confirm who holds their medical record, which entity charges their card, the pharmacy handling their prescription, and how to contact the prescriber.
The page's branded-drug trial figures do not prove clinical results for a preparation containing added vitamins. The old review's support-quality rating has been removed because no independent audit supports it.
Medication trials evaluate specific formulations, doses, and study populations. A provider advertising semaglutide or tirzepatide has not thereby demonstrated that its own treatment produces the results of Wegovy or Zepbound trials. A compounded medicine is not FDA-approved and should not be described as an approved generic equivalent.
Sources: FDA concerns with unapproved GLP-1 drugs used for weight loss · FDA clarification of compounding policies as GLP-1 supply stabilizes
Questions to ask before enrollment
- Who is responsible for my ongoing treatment and billing after the RXPros transition?
- Have my pharmacy, formula, concentration, or refill instructions changed?
- What exact medicine, formulation, and device would I receive, and which pharmacy dispenses it?
- Who prescribes in my state, and how do I obtain urgent clinical help?
- What will I pay at maintenance, and when do renewals and cancellation deadlines occur?
Ask the prescribing clinician how your other medicines, diabetes treatment, pregnancy plans, gastrointestinal history, and follow-up needs affect eligibility. Check the dispensing pharmacy with the relevant state board. A reassuring website or testimonial does not replace those checks.
Sources: FDA concerns with unapproved GLP-1 drugs used for weight loss
Confirm the practical effects of the RXPros transition
PriorityMeds' public announcement says RXPros now manages accounts, renewals, support, and transferred billing history. For an existing patient, that raises concrete continuity questions: who holds the medical record, which clinician continues prescribing, which pharmacy dispenses, and which entity appears on the payment statement? The announcement is a company description, not an independently audited guarantee that every detail remains unchanged.
Before the next refill, compare the new directions with the prior label. Confirm whether formula, concentration, device, and contact routes have changed. A billing transition and a clinical transition are different events, and one should not be assumed to resolve the other. Save the current agreement and ask whether prior prepaid balances or cancellation terms carry forward. We have not tested an account transfer or verified an individual patient's record.
B6 and B12 additions need their own rationale
The page advertises compounded tirzepatide with B6 and semaglutide with B12. Those combinations are separate preparations from approved Zepbound, Mounjaro, Ozempic, or Wegovy. A vitamin addition does not establish equivalent absorption, improved tolerability, or the same trial outcomes. Ask the clinician why the particular formulation is proposed and why an approved medicine does not meet the patient's need.
Request the complete ingredient list, pharmacy identity, concentration, and syringe instructions. Do not treat a website dosing menu as an individualized prescription. If concentration changes after the transition, an unchanged milligram dose can require a different volume. Have the dispensing pharmacist explain the current measurement before using familiar unit markings. Trial-style figures on a provider page are not evidence of outcomes for its added-vitamin compound.
Sources: PriorityMeds / RXPros official website · FDA concerns with unapproved GLP-1 drugs used for weight loss · FDA clarification of compounding policies as GLP-1 supply stabilizes
Review the advertised prices under the current agreement
The retrieved page lists $99.99 semaglutide and $144.97 tirzepatide monthly figures and describes a doctor visit and shipping as included. Ask RXPros which plan those figures apply to, what is due now, whether maintenance or higher doses cost more, and which renewal interval governs the account. The earlier PriorityMeds agreement should not be assumed to apply without confirmation.
Also establish how to cancel and how clinical pauses or eligibility decisions affect charges. A transferred billing history does not explain every future fee or refund rule. Compare a written quote with complete approved-product and other care pathways, keeping the formula distinction visible. Price, record continuity, dispensing quality, and clinical access are separate questions; we have not audited them and do not assign an overall score from the public announcement.
Sources: PriorityMeds / RXPros official website · FDA concerns with unapproved GLP-1 drugs used for weight loss
Sources and evidence
Provider sources support advertised services and terms. Clinical and regulatory sources explain medication and pharmacy considerations. These are distinct kinds of evidence.